telaglenastat + famotidine

Telaglenastat + famotidine is an investigational combination used to study potential drug-drug or pharmacokinetic interactions between telaglenastat, a small molecule glutaminase inhibitor, and famotidine, a histamine H2 receptor antagonist. Telaglenastat selectively inhibits kidney-type glutaminase (GLS), blocking glutamine metabolism in tumor cells and limiting their proliferation, and is being developed primarily for cancer therapy. Famotidine suppresses gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells and is commonly used for gastrointestinal disorders. The relevance of combining these drugs in clinical studies relates to their potential interaction, particularly as telaglenastat may have altered absorption if gastric pH is changed by famotidine. Famotidine itself has no direct anti-cancer mechanism; the combination is mainly to assess potential pharmacokinetic or safety effects in healthy adults.

Other names

famotidine + telaglenastat